GlassScriptPhysician profile
Steven Mortazavi
NPI 1902805252
$6,443.18
in general payments reported to CMS, 2019-2025
33 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,246 · 2020: $355 · 2021: $387 · 2022: $737 · 2023: $467 · 2024: $537 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $2,801.04 | 2019 | |
| Scilex Pharmaceuticals INC. | $756.80 | 2019-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $738.01 | 2019-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.06 | 2019-2025 | Relistor |
| Vertos Medical, INC. | $222.75 | 2022-2024 | Mild Device Kit |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Biodelivery Sciences International, INC. | $121.30 | 2020-2021 | |
| Si-Bone, INC. | $111.29 | 2019-2025 | |
| Foundation Fusion Solutions, LLC | $103.09 | 2021-2025 | |
| Grt US Holding, INC. | $89.83 | 2019-2021 | |
| Tersera Therapeutics LLC | $89.66 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $87.11 | 2025 | |
| Globus Medical, INC. | $81.61 | 2025 | Senza |
| Hikma Pharmaceuticals USA | $72.98 | 2022 | |
| Redhill Biopharma INC. | $48.70 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $43.18 | 2024 | Movantik |
| Medtronic, INC. | $39.25 | 2023 | Intellis Adaptivestim |
| Eisai INC. | $38.49 | 2020 | |
| Almatica Pharma LLC | $37.11 | 2022 | |
| Boston Scientific Corporation | $30.36 | 2020-2021 | |
| Allergan, INC. | $29.53 | 2020 | |
| Sanofi-Aventis U.S. LLC | $29.33 | 2019 | |
| Kaleo, INC. | $29.10 | 2019 | |
| Forte Bio-Pharma LLC | $26.92 | 2021 | |
| Stimwave Technologies Incorporated | $25.00 | 2019 | |
| Abbvie INC. | $24.74 | 2021 | |
| Averitas Pharma INC. | $22.10 | 2025 | Qutenza |
| Ermi LLC | $20.23 | 2025 | |
| Fidia Pharma USA INC. | $19.61 | 2023 | Hymovis |
| Ibsa Pharma INC. | $17.77 | 2020 | |
| Assertio Therapeutics, INC. | $16.96 | 2020 | |
| Pfizer INC. | $13.84 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mortazavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.